Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis

被引：0
|
作者：
Porter, J
Borgna-Pignatti, C
Baccarani, M
Saviano, A
Abish, S
Malizia, R
Nick, H
Opitz, H
Rabault, B
Gathmann, I
Marks, P
机构：
[1] Univ Coll Hosp, London, England
[2] Univ Ferrara, I-44100 Ferrara, Italy
[3] Policlin S Orsola, Bologna, Italy
[4] Azienda Ospe Rilievo Nazl A Cararelli, Naples, Italy
[5] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[6] Azienda Ospe Villa Sofia, Palermo, Italy
[7] Novartis, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2690
引用
下载
收藏
页码：755A / 756A
页数：2
相关论文
共 50 条
  • [41] Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Galanello, Renzo
    Piga, Antonio
    Williamson, Paul
    Porter, John B.
    BLOOD, 2007, 110 (11) : 816A - 816A
  • [42] Long-term efficacy and safety of deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD)
    Vichinsky, Elliott
    Coates, Thomas D.
    Thompson, Alexis A.
    Mueller, Brigitta U.
    Lagrone, Darlene
    Heeney, Matthew M.
    BLOOD, 2007, 110 (11) : 995A - 995A
  • [43] A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload:: a Phase I study in Japan
    Miyazawa, Keisuke
    Ohyashiki, Kazuma
    Urabe, Akio
    Hata, Tomoko
    Nakao, Shinji
    Ozawa, Keiya
    Ishikawa, Takayuki
    Kato, Junji
    Tatsumi, Yoichi
    Mori, Hiraku
    Kondo, Midori
    Taniguchi, Junsuke
    Tanii, Hiromi
    Rojkjaer, Lisa
    Omine, Mitsuhiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 88 (01) : 73 - 81
  • [44] Deferasirox (Exjade, ICL670) efficiently removes labile plasma iron as compared to desferioxamine and deferiprone: A 24-hour monitoring study in thalassemia major patients
    Zanninelli, G.
    Sorrentino, F.
    Iazzoni, R.
    Marzano, R.
    Breuer, W.
    Cabantchik, Z. I.
    Cianciulli, P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 536 - 537
  • [45] A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan
    Keisuke Miyazawa
    Kazuma Ohyashiki
    Akio Urabe
    Tomoko Hata
    Shinji Nakao
    Keiya Ozawa
    Takayuki Ishikawa
    Junji Kato
    Yoichi Tatsumi
    Hiraku Mori
    Midori Kondo
    Junsuke Taniguchi
    Hiromi Tanii
    Lisa Rojkjaer
    Mitsuhiro Omine
    International Journal of Hematology, 2008, 88 : 73 - 81
  • [46] Cost-effectiveness of once-daily oral chelation therapy with deferasirox (Exjade®, ICL670) versus infusional deferoxamine in transfusion-dependent thalassemic patients.
    Delea, TE
    Sofrygin, O
    Thomas, SK
    Baladi, JF
    Phatak, PD
    Coates, TD
    BLOOD, 2005, 106 (11) : 389A - 389A
  • [47] Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients.
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    Capdeville, Renaud
    BLOOD, 2006, 108 (11) : 503A - 503A
  • [48] The once-daily oral iron chelator deferasirox (Exjade®, ICL670) is effective and generally well tolerated during long-term treatment in pediatric patients
    Vichinsky, E.
    Paley, C.
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 608 - 609
  • [49] A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
    Cappellini, MD
    Cohen, A
    Piga, A
    Bejaoui, M
    Perrone, S
    Agaoglu, L
    Aydinok, Y
    Kattamis, A
    Kilinc, Y
    Porter, J
    Capra, M
    Galanello, R
    Fattoum, S
    Drelichman, G
    Magnano, C
    Verissimo, M
    Athanassiou-Metaxa, M
    Giardina, P
    Kourakli-Symeonidis, A
    Janka-Schaub, G
    Coates, T
    Vermylen, C
    Olivieri, N
    Thuret, I
    Opitz, H
    Ressayre-Djaffer, C
    Marks, P
    Alberti, D
    BLOOD, 2006, 107 (09) : 3455 - 3462
  • [50] Impact of long-term deferasirox (EXJADE®, ICL670) treatment in maintaining or reducing serumferritin levels, and outcome of dose adjustments
    Porter, J.
    Cohen, A.
    Agaoglu, L.
    Ganser, A.
    Cappellini, M. D.
    Maseruka, H.
    Glimm, E.
    Albert, D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 541 - 541
12345